



[www.aphc.info](http://www.aphc.info)



Introduction – *Patrick Marcellin (France)*

*Chairs: Massimo Colombo (Italy) and Michael Fried (USA)*

Western Countries

*Speakers: Michael Fried (USA), Maria Buti (Spain), Massimo Colombo (Italy), Graham Foster (UK), Victor de Ledinghen (France), Thomas Berg (Germany)*

Other Countries

*Speakers: Mustapha Benazzouz (Morocco), Robert Flisiak (Poland), Vasily Isakov (Russia), Adriana Popescu (Romania), Raymundo Parana (Brazil), Gamal Esmat (Egypt)*

Special Communication : *How to manage liver patients during war :Nabil Antaki (Syria)*

*PHC 2018 - [www.aphc.info](http://www.aphc.info)*

**15 & 16 January 2018 / PARIS** - Palais des Congrès

# Current situation C in England

- ✓ Prevalence – ~ **0.3-0.4%**
- ✓ Total number of patients – **100,000- 160,000**
- ✓ Mortality – **450 per year**
- ✓ Number of liver transplantations **150 per year**
- ✓ Total number of patients treated by DAAs so far **20,000**
- ✓ Total number of patients treated by DAAs in 2017 **11,000**

# Current resources and programs for HCV

- ✓ Current resources provided by Health Authorities
  - ✓ DAAs available **All (choice dictated by price)**
  - ✓ Program for screening – **major evidence based initiatives (HepFREE trial in immigrants, mandatory prisoner and PWID ‘opt-out’)**
  - ✓ Program to improve access to treatment – **evidence based initiatives – HepCATT, incentives to pharma**

# Future actions planned

- ✓ To improve screening – **funded incentives**
- ✓ To facilitate access to treatment – **funded incentives**
- ✓ Future drugs available
- ✓ Other major action – **elimination in 5 years is planned**